World’s best-selling drug costs five times more in U.S. than Europe

Critics accuse the maker of Humira of exploiting U.S. patent laws to keep competitors’ less expensive versions off the market. The company, AbbVie, says it’s balancing the need to keep the drug affordable to patients with the need to fund new drug development.Feb. 19, 2019